OP Asset Management Ltd Invests $11.93 Million in BioCryst Pharmaceuticals, Inc. $BCRX

OP Asset Management Ltd acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,252,863 shares of the biotechnology company’s stock, valued at approximately $11,927,000. OP Asset Management Ltd owned about 0.50% of BioCryst Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in BCRX. Royal Bank of Canada lifted its holdings in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in BioCryst Pharmaceuticals by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after purchasing an additional 8,517 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after purchasing an additional 640,704 shares during the period. Caxton Associates LLP bought a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of BioCryst Pharmaceuticals by 11.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after buying an additional 47,355 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $9.97 on Thursday. The company has a 50-day moving average of $8.88 and a 200-day moving average of $8.23. The company has a market capitalization of $2.53 billion, a price-to-earnings ratio of -5.60 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $10.32.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. During the same period in the previous year, the firm earned $0.20 EPS. The business’s revenue was up 7.5% compared to the same quarter last year. Sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current year.

Analyst Upgrades and Downgrades

BCRX has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Needham & Company LLC cut their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Wedbush decreased their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Citizens Jmp lifted their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.